Stocks of the Hour: Atomo Diagnostics, AdAlta, Aruma Resources
A snapshot of the stocks on the move, featuring Atomo Diagnostics (ASX:AT1), AdAlta (ASX:1AD) and Aruma Resources (ASX:AAJ).
Read More
Atomo Diagnostics Limited
Atomo’s innovative rapid diagnostic test (RDT) platforms simplify procedures, mitigate common user errors, and enhance test performance. Their unmatched usability has won the respect of frontline healthcare providers worldwide, and has made Atomo the OEM partner of choice for diagnostic companies wanting to enhance their RDT product offerings.
Atomo’s all-in-one RDT platforms put the end user first and make it easy to test and screen for a range of infectious diseases and chronic conditions.
Their unmatched usability has won the respect of frontline healthcare providers worldwide, and has made Atomo the OEM partner of choice for diagnostic manufacturers looking to transform their RDT offerings.
Award-winning Australian innovation
Atomo Diagnostics is a specialist medical device design innovator and original equipment manufacturing (OEM) company whose unique proprietary technologies support usability, accuracy, and safety. Headquartered in Sydney, Australia, Atomo has emerged as a global leader in the development of point of care devices for rapid diagnostic testing (RDT).
Atomo’s operations are ISO 13485 certified for the design, development, and manufacture of in vitro diagnostic medical devices.
Atomo’s operations are ISO 13485 certified for the design, development, and manufacture of in vitro diagnostic medical devices.
Designed for simplicity
Atomo’s device solutions address challenges associated with in-field deployment of standard RDT kits. The focus on usability and simplicity in design means Atomo’s integrated RDT platforms are easy to learn and teach, and suitable for use in a variety of real world settings, including doctor’s offices, pharmacies, point of care settings, community clinics, and the home.
AtomoRapid™ RDT platforms are customisable to suit a variety of blood-based lateral flow test assays and are appropriate for a range of applications, including screening for chronic conditions and detection of infectious diseases.
AtomoRapid™ RDT platforms are customisable to suit a variety of blood-based lateral flow test assays and are appropriate for a range of applications, including screening for chronic conditions and detection of infectious diseases.
Spotlight Videos
Stocks of the Hour: Atomo Diagnostics, AdAlta, Aruma Resources
A snapshot of the stocks on the move, featuring Atomo Diagnostics (ASX:AT1), AdAlta (ASX:1AD) and Aruma Resources (ASX:AAJ).
WATCH VIDEOAll Atomo Diagnostics Limited Content
News
Atomo Diagnostics (ASX: AT1) – Webinar Presentation
Will Souter - CFO - Atomo Diagnostics is a global leader in the user-centered design of innovative, accurate and reliable rapid diagnostics.
Read More
Rapid diagnostic testing devices
John Kelly - Founder, Managing Director & CEO - Atomo Diagnostics Limited is a global leader in the design of medical devices for blood-based rapid testing for professional use and self-testing.
Read More
